Abbott Laboratories Stock Forecast for 2023 - 2025 - 2030
Updated on 05/27/2023
Abbott Laboratories Stock Forecast and Price Target
Abbott Laboratories's stock price reaches the average target of $125.00 by 2024 as expected recently by fiveteen notable experts, there would be a potential upside of approximately 21.51% from the last closing price in May, 2023. This possible increase is based on a high estimate of $140.00 and a low estimate of $104.00. If you are interested in ABT stock, it is important to also consider its competitors.
21.51% Upside
Abbott Laboratories Fair Value Forecast for 2023 - 2025 - 2030
In the last three years, Abbott Laboratories's Price has grown by 23.77%, rising from $86.02 to $106.47. For next year, analysts predict Fair Value of $132.75, which would mean an increase of 24.69%. Over the next eight years, experts predict that Abbott Laboratories's Fair Value will grow at a rate of 59.87%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| ISRG Stock Forecast | Intuitive Surgical Inc | Outperform |
13
|
$306.90 | Buy/Sell | $305.24 | -8.11% |
| BSX Stock Forecast | Boston Scientific | Outperform |
15
|
$51.06 | Buy/Sell | $52.51 | -2.08% |
| DXCM Stock Forecast | DexCom | Outperform |
16
|
$115.05 | Buy/Sell | $129.69 | 9.08% |
| RMD Stock Forecast | ResMed | Outperform |
17
|
$215.44 | Buy/Sell | $251.67 | 17.20% |
| PODD Stock Forecast | Insulet | Outperform |
15
|
$272.63 | Buy/Sell | $302.13 | 17.38% |
Abbott Laboratories Revenue Forecast for 2023 - 2025 - 2030
In the last three years, Abbott Laboratories's Revenue has grown by 35.01%, rising from $31.90B to $43.08B. For the following year, the 23 analysts predict that Abbott Laboratories's Revenue will drop by 3.92%, reaching $41.39B. Over the next eight years, experts predict that Abbott Laboratories's Revenue will grow at a rate of 13.51%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| NYSE:VAR Stock Forecast | Varian Medical Systems | - |
16
|
$0.00 | Buy/Sell | $0.00 | 0.00% |
| MASI Stock Forecast | Masimo | Outperform |
14
|
$157.35 | Buy/Sell | $166.14 | 8.04% |
| SWAV Stock Forecast | ShockWave Medical | Outperform |
4
|
$280.67 | Buy/Sell | $0.00 | -35.87% |
.jpg)
Abbott Laboratories Dividend per Share Forecast for 2023 - 2025 - 2030
In the last three years, Abbott Laboratories's Dividend per Share has grown, rising from $1.32 to $2.04 – a growth of 54.55%. In the following year, the 10 analysts surveyed believe that Abbott Laboratories's Dividend per Share will decrease by 3.92%, reaching $1.96. For the next eight years, the forecast is for Dividend per Share to grow by 24.46%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| LVGO Stock Forecast | Livongo Health | - |
0
|
$0.00 | Buy/Sell | $0.00 | 0.00% |
| INSP Stock Forecast | Inspire Medical Systems | Outperform |
6
|
$294.29 | Buy/Sell | $0.00 | 1.94% |
| CMD Stock Forecast | Cantel Medical | - |
17
|
$0.07 | Buy/Sell | $85.00 | 199600.00% |
Abbott Laboratories Free Cash Flow Forecast for 2023 - 2025 - 2030
Abbott Laboratories's Free Cash Flow has seen impressive growth In the last three years, rising from $4.50B to $9.81B – a growth of 118.16%. According to the 6 analysts polled, in the next year, Abbott Laboratories's Free Cash Flow will fall by 12.74%, reaching $8.56B. For the next eight years, the forecast is for Free Cash Flow to grow by 11.77%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| AXNX Stock Forecast | Axonics | Buy |
7
|
$51.19 | Buy/Sell | $0.00 | 40.65% |
| IRTC Stock Forecast | iRhythm Technologies | Hold |
11
|
$119.30 | Buy/Sell | $0.00 | 29.09% |
| CNMD Stock Forecast | CONMED | Outperform |
16
|
$118.33 | Buy/Sell | $145.00 | 1.41% |
Abbott Laboratories Net Income Forecast for 2023 - 2025 - 2030
Abbott Laboratories's Net Income has grown In the last three years, rising from $3.69B to $7.07B – a growth of 91.78%. In the next year, analysts believe that Net Income will reach $8.79B – an increase of 24.32%. For the next eight years, experts predict that Abbott Laboratories's Net Income will grow at a rate of 59.74%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| TNDM Stock Forecast | Tandem Diabetes Care | Outperform |
9
|
$26.57 | Buy/Sell | $127.93 | 246.26% |
| ITGR Stock Forecast | Integer Holdings | Buy |
16
|
$80.37 | Buy/Sell | $111.33 | 35.62% |
| GNMK Stock Forecast | GenMark Diagnostics | - |
2
|
$0.00 | Buy/Sell | $24.05 | 0.00% |
Abbott Laboratories EBITDA Forecast for 2023 - 2025 - 2030
In the last three years, Abbott Laboratories's EBITDA has grown by 58.06%, rising from $7.77B to $12.28B. For the next year, 11 analysts project Abbott Laboratories's EBITDA to drop by 2.79%, reaching $11.94B. Over the next eight years, experts believe that Abbott Laboratories's EBITDA will grow at a rate of 5.59%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| NVRO Stock Forecast | Nevro | Hold |
6
|
$27.56 | Buy/Sell | $69.50 | 134.03% |
| SILK Stock Forecast | Silk Road Medical, Inc | Outperform |
7
|
$30.65 | Buy/Sell | $0.00 | 69.66% |
| TMDX Stock Forecast | TransMedics Group | Outperform |
8
|
$70.68 | Buy/Sell | $0.00 | -60.38% |
Abbott Laboratories EBIT Forecast for 2023 - 2025 - 2030
In the last two years, Abbott Laboratories's EBIT has grown, moving from $4.76B to $9.22B – an increase of 93.78%. In the next year, analysts predict that EBIT will jump to $10.32B – up 11.95% from the current level. Looking ahead to eight years, experts forecast that EBIT will grow by 43.17%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| NTUS Stock Forecast | Natus Medical | - |
14
|
$32.96 | Buy/Sell | $36.00 | 70.27% |
| CUTR Stock Forecast | Cutera | Buy |
6
|
$16.64 | Buy/Sell | $42.20 | 368.75% |
| SENS Stock Forecast | Senseonics Holdings | Hold |
6
|
$0.66 | Buy/Sell | $0.00 | 278.79% |
Abbott Laboratories EPS Price Prediction Forecast for 2023 - 2025 - 2030
In the last three years, Abbott Laboratories's EPS has grown by 23.77%, rising from $3.24 to $4.01. For next year, analysts predict EPS of $5.00, which would mean an increase of 24.69%. Over the next eight years, experts predict that Abbott Laboratories's EPS will grow at a rate of 59.87%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| INGN Stock Forecast | Inogen | Outperform |
8
|
$11.11 | Buy/Sell | $44.00 | 188.03% |
| QTRX Stock Forecast | Quanterix | Buy |
11
|
$20.79 | Buy/Sell | $0.00 | 75.57% |
| VRAY Stock Forecast | ViewRay | Outperform |
7
|
$0.53 | Buy/Sell | $0.00 | 1503.77% |
Site Navigation
.jpg)